

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

#### **TCT-63**

# North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital Mortality


Payam Dehghani,¹ Christian Schmidt,² Ross Garberich,³
Santiago Garcia,³ Cindy Grines,⁴ Rajan Patel,⁵
Cristina Sanina,⁶ Wah Wah Htun,ˀ Keshav Nayak,⁶ M Chadi Alraies,⁶
Nima Ghasemzadeh,¹⁰ Laura Davidson,¹¹ Deepak Acharya,¹²
Jay Stone,¹³ Tareq Alyousef,¹⁴ Brian Case,¹⁵ Xuming Dai,¹⁶
Abdul Moiz Hafiz,¹ˀ Mina Madan,¹ፆ Farouc Amin Jaffer,¹⁰
Jay Shavadia,²⁰ Timothy Henry²¹

<sup>1</sup>Prairie Vascular Research Inc, Regina, Saskatchewan, Canada; <sup>2</sup>Minneapolis Heart Institute, Minneapolis, Minnesota, USA; <sup>3</sup>Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA; <sup>4</sup>Northside Hospital, Atlanta, Georgia, USA; <sup>5</sup>Ochsner Clinic Foundation, New Orleans, Louisiana, USA; <sup>6</sup>Montefiore Medical Center, Bronx, New York, USA; <sup>7</sup>Gundersen Health System, La Crosse, Wisconsin, USA; <sup>8</sup>Scripps Mercy, San Diego, California, USA; <sup>9</sup>Detroit Medical Center, Detroit, Michigan, USA; <sup>10</sup>The Heart Center of Northeast Georgia, Duluth, Georgia, USA; <sup>11</sup>Northwestern University/ Northwestern Medicine, Chicago, Illinois, USA; <sup>12</sup>University of Arizona, Tucson, Arizona, USA; <sup>13</sup>Shore Cardiac Institute BHMG, Toms River, New Jersey, USA; <sup>14</sup>Cook County Health System, Chicago, Illinois, USA; <sup>15</sup>MedStar Washington Hospital Center, Washington, DC, USA; <sup>16</sup>New York Presbyterian Queens, Flushing, New York, USA; <sup>17</sup>SIU School Of Medicine, Springfield, Illinois, USA; <sup>18</sup>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>19</sup>Massachusetts General Hospital/ Harvard Medical School, Boston, Massachusetts, USA; <sup>20</sup>Royal University Hospital, Saskatoon, Saskatchewan, Canada; <sup>21</sup>The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, USA

**BACKGROUND** Although in-hospital mortality for COVID-confirmed (COVID+) patients presenting with ST-elevated myocardial infarction (STEMI) is high, its predisposing risk factors—and, in particular, the cumulative risk rendered by their combination—is unknown. We sought to develop a risk score of in-hospital mortality in COVID+ patients presenting with STEMI.

**METHODS** Baseline clinical and procedural characteristics of COVID+patients presenting with STEMI in the North American COVID-19 Myocardial Infarction (NACMI) registry were evaluated as univariable predictors of in-hospital mortality. A backwards, stepwise, logistic regression was used to create a multivariable model to identify independent predictors of in-hospital mortality with an inclusion P value < 0.1. Based on the model, 7 identified variables (age > 55, shock prepercutaneous coronary intervention, diabetes, mechanical ventilation, dyspnea on presentation, infiltrates on chest x-ray, and cardiopulmonary mechanical support) were assigned a weighted integer; the sum of the integers was a total risk score of in-hospital morality for each patient.

**RESULTS** The overall occurrence of in-hospital mortality in 370 COVID-19+ cases presenting with STEMI was 28%. In-hospital mortality increased exponentially with increasing risk score (Cochran Armitage chi-square, P < 0.001), and the model demonstrated good discriminative power (C-statistic = 0.85). The increasing risk score was strongly associated with in-hospital mortality (range < 1% to 65% for a low- and very high-risk score, respectively; see Figure 1).



**CONCLUSION** The risk of in-hospital mortality in COVID+ patients presenting with STEMI can be simply assessed using readily available information.

CATEGORIES CORONARY: Acute Myocardial Infarction

#### **TCT-64**

## Racial Differences and In-Hospital Mortality Associated With Stress-Induced Cardiomyopathy During the COVID-19 Pandemic



Banveet Kaur Khetarpal, Awad Javaid, Christoph Sossou,
Ariyon Schreiber, Chowdhury Ahsan, Komandoor Srivathsan
UNLV School of Medicine, Las Vegas, Nevada, USA; Kirk Kerkorian
School of Medicine at UNLV, Las Vegas, Nevada, USA; UNLV School of
Medicine, Las Vegas, Nevada, USA; UNLV School of Medicine, Las
Vegas, Nevada, USA; University Medical Center, Las Vegas, Las Vegas,
Nevada, USA; Mayo Clinic Arizona, Phoenix and Scottsdale, Arizona,
USA

BACKGROUND Multiple studies have shown a significantly increased incidence of stress-induced cardiomyopathy (SICM) during the COVID-19 pandemic, likely owing to the psychosocial, economic, and physical stressors imposed on people's lives. Our aim is to study the incidence of SICM and its anatomic variants during the COVID-19 pandemic and to evaluate the impact of demographic, social, and economic factors.

**METHODS** We performed a retrospective analysis of patients admitted to the 3 Mayo Clinic centers (Minnesota, Arizona, Florida) between January 1, 2020, and December 31, 2020. Patients with SICM were identified using the ICD-10 code I51.81. All patients with SICM were divided into COVID-19-positive and COVID-19-negative groups for comparison. Patients who were not tested were excluded.

**RESULTS** A total of 197 patients (mean age 67.4  $\pm$  15.1 years, 72.6% female, 9.1% COVID-19 positive) were diagnosed with SICM during the 1-year study period. Overall, patients with SICM had median lengths of stay (LOS) of 6 days, in-hospital mortality rate of 12.2%, and a 30-day readmission rate of 22.8%. A lower proportion of Whites (77.8% vs 99.2%) and Hispanics (0.0% vs 2.2%) and a higher proportion of Blacks (5.6% vs 3.9%), Asians (5.6% vs 1.1%), and American Indians (5.6% vs 0.0%) with SICM were COVID-19 positive, and this racial difference was statistically significant (P=0.02). Interestingly, the mortality rate was lower (11.1% vs 10.6%, P=0.05) in patients with SICM and COVID-19. The 2 groups were not significantly different for marital status, insurance type, anatomic variants, left ventricular ejection fraction, and 30-day readmission rates.

Patient characteristics	All patients (N = 197)	COVID-19 positive (N = 18)	COVID-19 negative (N = 179)	<i>P</i> value
Women, N (%)	143 (72.6)	12 (66.7)	131 (73.2)	0.583
Race N (%): White, Black, Hispanic, Asian American Indian,Alaskan Native/unknown	179(90.9) 8 (4.1) 4 (2.0) 3 (1.5) 1 (0.5) 2 (1.0)	14(77.8) 1 (5.6) 0 (0.0) 1 (5.6) 1 (5.6) 1 (5.6)	165(92.2) 7 (3.9) 4 (2.2) 2 (1.1) 0 (0.0) 1 (0.6)	0.024
Marital status: married, single	116 (58.9) 81(41.1)	11(61.1) 7 (38.9)	105 (58.7) 74 (41.3)	1.000
Insurance, N (%) public, private, uninsured	153 (77.7) 41 (20.8) 3 (1.5)	14(77.8) 4 (22.2) 0 (0.0)	139 (77.7) 37 (20.7) 3 (1.7)	1.000
SICM variant, N (%) Apical midventricular basal	168(85.3) 17 (8.6) 12 (6.1)	15(83.4) 2 (11.1) 1 (5.6)	153(85.5) 15 (8.4) 11 (6.1)	0.865
LVEF (%), mean $\pm$ SD	37.3 ± 10.6	36.8 ± 10.9	37.3 ± 10.6	0.849
30-day readmission, N (%)	45 (22.8)	2 (11.1)	43 (24.0)	0.375
In-hospital mortality, N (%)	24 (12.2)	5 (11.1)	19 (10.6)	0.050

SD = standard deviation

**CONCLUSION** SICM usually occurs in the 6th to 7th decade of life and has a higher incidence in women. Racial minorities with SICM were disproportionately affected during the pandemic with a higher incidence of COVID-19. However, in-hospital mortality rates were lower in COVID-19- positive patients with SICM.

**CATEGORIES STRUCTURAL:** Congenital and Other Structural Heart Disease

### TCT-65

## Characteristics of COVID-19 Patients With Thrombosis and Impact on Clinical Outcomes

